Effects of metformin hydrochloride on the endothelial function of type 2 diabetes mellitus rats with high blood glucose fluctuation

Chinese Pharmacological Bulletin

Volumn 27, Issue 5, 2011, Pages 686-690

  Wang, Jing Shang ^a   Yin, Hui Jun ^a   Huang, Ye ^a   Liu, Qian ^a   Guo, Chun Yu ^a   Xia, Cheng Dong ^a  

^a INSTITUTE OF CHINESE MATERIA MEDICA   (China)

Author keywords

Advanced glycation end products; Endothelial function; Glucose fluctuation model; Hepatocyte growth factor; High blood glucose fluctuation; Metformin hydrochloride; Type 2 diabetes mellitus

Indexed keywords

ADVANCED GLYCATION END PRODUCT; GLUCOSE; INTERCELLULAR ADHESION MOLECULE 1; METFORMIN; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; SCATTER FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM; GLUCOSE BLOOD LEVEL; LIPID DIET; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT; STREPTOZOCIN DIABETES;

EID: 80051652176     PISSN: 10011978     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1001-1978.2011.05.021     Document Type: Article

References (21)

1. Guerci B, Kearney-Schwartz A, Böhme P, et al. Endothelial dysfunction and type 2 diabetes. Part1: physiology and methods for exploring the endothelial function [J]. Diabetes Metab, 2001,27 (4 Pt 1):425-34.
2. Hirsch I B, Brownlee M. Should minimal blood-variability become the gold standard of glycemic control [J]? J Diabetes Complications, 2005,19:178-81. (Pubitemid 40615551)
3. Monnier L, Colette C. Glycemic variability: should we and can we prevent it [J]? Diabetes Care, 2008,31(Suppl 2):S150-4.
4. O' Sullivan E P, Dinneen S F. Benefits of early intensive glucose control to prevent diabetes complications were sustained for up to 10 years [J]. Evid Based Med, 2009,14(1):9-10.
5. Anfossi G, Russo I, Bonomo K, Trovati M. The cardiovascular effects of metformin : further reasons to consider an old drug as a cornerstone in the therapy of type 2 diabetes mellitus [J]. Curr Vasc Pharmacol, 2010,8(3):327-37.
6. Bailey C J. Metformin; effects on micro and macrovascular complications in type 2 diabetes [J]. Cardiovasc Drugs Ther, 2008,22(3):215-24.
7. Paulsen T. How much do you know about metformin [J]? Diabetes Self Manag, 2010,27(4):28-30.
8. Guerci B, Bohme P, Kearney Schwartz A, et al. Endothelial dysfunction and type 2 diabetes. Part2: altered endothelial function and the effects of treatments in type 2 diabetes mellitus [J]. Diabetes Metab, 2001,27:436-47.
9. Boneti P O, Lerman L O, Lerman A. Endothelial dysfunction, a marker of atherosclerotic risk [J]. Arterioscler Thromb Vasc Biol, 2003,23:168-75. (Pubitemid 36231924)
10. Mao S M, Li C D, Wang L, et al. Effect and mechanism of astragalus polysaccharides on apoptosis of the islet beta cell in diabetes mellitus rats [J]. Chin Pharmacol Bull, 2009,25(9):1227-9.
11. Nie X Q, Yu L H, Chen H H, et al. Intervention effects of rutaecarpine in type 2 diabetic obese rats [J]. Chin Pharmacol Bull, 2010,26(7):872-6.
12. Ceriello A, Esposito K, Piconi L, et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients [J]. Diabetes, 2008,57(5):1349-54.
13. Quagliaro L, Piconi L, Assaloni R, et al. Intermittent high glucose enhances ICAM-1, VCAM-1 and E-selectin expression in human umbilical vein endothelial cells in culture: the distinct role of protein kinase C and mitochondrial superoxide production [J]. Atherosclerosis, 2005,183(2):259-67.
14. Piconi L, Quagliaro L, Assaloni R, et al. Constant and intermittent high glucose enhances endothelial cell apoptosis through mitochondrial superoxide overproduction [J]. Diabetes Metab Res Rev, 2006,22(3):198-203. (Pubitemid 43805400)
15. Piconi L, Corgnali M, Da Ros R, et al. The protective effect of rosuvastatin in human umbilical endothelial cells exposed to constant or intermittent high glucose [J]. J Diabetes Complications, 2008, 22(1):38-45.
16. Yao Q X, Qi Z Q, Wang G, et al. Arecoline improved glucose and lipid metabolism in type 2 diabetic rats [J]. Chin Pharmacol Bull, 2009,25(11):1477-81.
17. Lu Y, Wang L H, Wang N, et al. The measurement and clinical evaluation of antioxiygenic ability of diabetic rats with insulin resistance [J]. Chin Pharmacol Bull, 2009,25(6):836-7.
18. Chinese Diabetes Society. The 2007 Guideline of Nationa Type 2 Diabetes Prevents and Controls [J]. Natl Med J China, 2008,88 (18):1227-45.
19. Agarwal N, Rice S P, Bolusani H, et al. Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial [J]. J Clin Endocrinol Metab, 2010,95(2):722-30.
20. Chen L L, Liao Y F, Zeng T S, et al. Effects of metformin plus gliclazide compared with metformin alone on circulating endothelial progenitor cell in type 2 diabetic patients [J]. Endocrine, 2010, 38(2):266-75.
21. Alexanderson-Rosas E, de Jesus Martinez A, Ochoa-Lopez J M, et al. Effects of the combined treatment with Metformin/Glimepiride on endothelial function of patients with type 2 diabetes mellitus. A positron emission tomography (PET) evaluation study [J]. Arch Cardiol Mex, 2009,79(4):249-56.